Oliver Höppner

Drug Response Dx GmbH develops biomarker test kit for rheumatoid arthritis treatment. Its product allows users to classify RA patients as responder or non-responder to TNF-alpha blockers. The company was founded by Zoltán Konthur, Jörg Michael Hollidt, Karl Skriner and Joachim Rautter in February 2012 and is headquartered in Hennigsdorf, Germany.

NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany.

BIOTECTID GmbH chronic inflammatory diseases still give sleepless nights, not only to patients, but also to the treating physicians. Diagnosis and treatment in this field is far more difficult than in cases of acute illness. One example of a chronic-inflammatory disease is rheumatoid arthritis, rheumatism of the joints. A prerequisite for accurately effective and compatible therapies here is to precisely locate the site, extent and intensity of the source of inflammation occurring, and its progression in the further course of the disease. In order for physicians to have more success in this field in future, the employees of BIOTECTID have been tackling this problem for many years and have been able to achieve impressive results: Coming from the research field of immunology, they developed a diagnostic agent based on monoclonal antibodies. Through this, they are very familiar with the immune system. The drug is currently in the first of three clinical test phases. It is manufactured and tested at BIOTECTID by a highly qualified workforce, and corresponds to the demanding EU standards of the Directive for Good Manufacturing Practice (GMP). This diagnostic agent forms the basis of routine examinations that will be possible in every nuclear-medical practice. In a few years they want to be able to help rheumatism patients and rheumatologists sleep soundly again.